Effect of combination antiretroviral therapy on cerebrospinal fluid HIV RNA, HIV resistance, and clinical manifestations of encephalopathy

Cynthia McCoig, Maria Mercedes Castrejón, Elizabeth Castaño, Onix De Suman, Carmen Báez, Wilfrido Redondo, Daniel McClernon, Susan Danehower, E. Randall Lanier, Carol Richardson, Amy Keller, Seth Hetherington, Xavier Sáez-Llorens, Octavio Ramilo

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Objectives: This study evaluated the effect of treatment with abacavir/lamivudine/zidovudine versus lamivudine/zidovudine on cerebrospinal fluid (CSF) human immunodeficiency virus (HIV) RNA and clinical manifestations of HIV encephalopathy in children. Study design: HIV-infected children 7 months to 10 years of age (n = 23) were studied. CSF and plasma were obtained at baseline and weeks 8, 16, and 48. Genotype analysis of HIV was attempted at baseline and week 48. Neurologic evaluations were performed at baseline and weeks 16, 32, and 48. Results: At baseline, 83% of children had >2.00 log10 copies/mL HIV RNA in CSE but only 10% had HIV RNA measurable at week 48. Among children in whom paired genotyping of HIV was possible, 8 of 11 had identical patterns in both CSF and plasma at baseline, whereas at week 48, only 1 of 9 children had similar patterns. Neurologic abnormalities were observed in 83% of children at baseline but only 35% of children at week 48 (P = .004), suggesting a benefit of treatment. Conclusions: Antiretroviral therapy was associated with a decline in CSF HIV RNA and an improvement in neurologic status. The development of genotypic mutations was different in CSF and plasma, suggesting discordant viral evolution. These results suggest that antiretroviral treatment in children should include agents with activity in the CNS.

Original languageEnglish (US)
Pages (from-to)36-44
Number of pages9
JournalJournal of Pediatrics
Volume141
Issue number1
DOIs
StatePublished - 2002
Externally publishedYes

Fingerprint

Brain Diseases
Cerebrospinal Fluid
HIV
RNA
Zidovudine
Therapeutics
Nervous System
Nervous System Malformations
Lamivudine
Genotype
Mutation

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Effect of combination antiretroviral therapy on cerebrospinal fluid HIV RNA, HIV resistance, and clinical manifestations of encephalopathy. / McCoig, Cynthia; Castrejón, Maria Mercedes; Castaño, Elizabeth; De Suman, Onix; Báez, Carmen; Redondo, Wilfrido; McClernon, Daniel; Danehower, Susan; Lanier, E. Randall; Richardson, Carol; Keller, Amy; Hetherington, Seth; Sáez-Llorens, Xavier; Ramilo, Octavio.

In: Journal of Pediatrics, Vol. 141, No. 1, 2002, p. 36-44.

Research output: Contribution to journalArticle

McCoig, C, Castrejón, MM, Castaño, E, De Suman, O, Báez, C, Redondo, W, McClernon, D, Danehower, S, Lanier, ER, Richardson, C, Keller, A, Hetherington, S, Sáez-Llorens, X & Ramilo, O 2002, 'Effect of combination antiretroviral therapy on cerebrospinal fluid HIV RNA, HIV resistance, and clinical manifestations of encephalopathy', Journal of Pediatrics, vol. 141, no. 1, pp. 36-44. https://doi.org/10.1067/mpd.2002.125007
McCoig, Cynthia ; Castrejón, Maria Mercedes ; Castaño, Elizabeth ; De Suman, Onix ; Báez, Carmen ; Redondo, Wilfrido ; McClernon, Daniel ; Danehower, Susan ; Lanier, E. Randall ; Richardson, Carol ; Keller, Amy ; Hetherington, Seth ; Sáez-Llorens, Xavier ; Ramilo, Octavio. / Effect of combination antiretroviral therapy on cerebrospinal fluid HIV RNA, HIV resistance, and clinical manifestations of encephalopathy. In: Journal of Pediatrics. 2002 ; Vol. 141, No. 1. pp. 36-44.
@article{c6ea75eee65c4372bc90366a6eab13fa,
title = "Effect of combination antiretroviral therapy on cerebrospinal fluid HIV RNA, HIV resistance, and clinical manifestations of encephalopathy",
abstract = "Objectives: This study evaluated the effect of treatment with abacavir/lamivudine/zidovudine versus lamivudine/zidovudine on cerebrospinal fluid (CSF) human immunodeficiency virus (HIV) RNA and clinical manifestations of HIV encephalopathy in children. Study design: HIV-infected children 7 months to 10 years of age (n = 23) were studied. CSF and plasma were obtained at baseline and weeks 8, 16, and 48. Genotype analysis of HIV was attempted at baseline and week 48. Neurologic evaluations were performed at baseline and weeks 16, 32, and 48. Results: At baseline, 83{\%} of children had >2.00 log10 copies/mL HIV RNA in CSE but only 10{\%} had HIV RNA measurable at week 48. Among children in whom paired genotyping of HIV was possible, 8 of 11 had identical patterns in both CSF and plasma at baseline, whereas at week 48, only 1 of 9 children had similar patterns. Neurologic abnormalities were observed in 83{\%} of children at baseline but only 35{\%} of children at week 48 (P = .004), suggesting a benefit of treatment. Conclusions: Antiretroviral therapy was associated with a decline in CSF HIV RNA and an improvement in neurologic status. The development of genotypic mutations was different in CSF and plasma, suggesting discordant viral evolution. These results suggest that antiretroviral treatment in children should include agents with activity in the CNS.",
author = "Cynthia McCoig and Castrej{\'o}n, {Maria Mercedes} and Elizabeth Casta{\~n}o and {De Suman}, Onix and Carmen B{\'a}ez and Wilfrido Redondo and Daniel McClernon and Susan Danehower and Lanier, {E. Randall} and Carol Richardson and Amy Keller and Seth Hetherington and Xavier S{\'a}ez-Llorens and Octavio Ramilo",
year = "2002",
doi = "10.1067/mpd.2002.125007",
language = "English (US)",
volume = "141",
pages = "36--44",
journal = "Journal of Pediatrics",
issn = "0022-3476",
publisher = "Mosby Inc.",
number = "1",

}

TY - JOUR

T1 - Effect of combination antiretroviral therapy on cerebrospinal fluid HIV RNA, HIV resistance, and clinical manifestations of encephalopathy

AU - McCoig, Cynthia

AU - Castrejón, Maria Mercedes

AU - Castaño, Elizabeth

AU - De Suman, Onix

AU - Báez, Carmen

AU - Redondo, Wilfrido

AU - McClernon, Daniel

AU - Danehower, Susan

AU - Lanier, E. Randall

AU - Richardson, Carol

AU - Keller, Amy

AU - Hetherington, Seth

AU - Sáez-Llorens, Xavier

AU - Ramilo, Octavio

PY - 2002

Y1 - 2002

N2 - Objectives: This study evaluated the effect of treatment with abacavir/lamivudine/zidovudine versus lamivudine/zidovudine on cerebrospinal fluid (CSF) human immunodeficiency virus (HIV) RNA and clinical manifestations of HIV encephalopathy in children. Study design: HIV-infected children 7 months to 10 years of age (n = 23) were studied. CSF and plasma were obtained at baseline and weeks 8, 16, and 48. Genotype analysis of HIV was attempted at baseline and week 48. Neurologic evaluations were performed at baseline and weeks 16, 32, and 48. Results: At baseline, 83% of children had >2.00 log10 copies/mL HIV RNA in CSE but only 10% had HIV RNA measurable at week 48. Among children in whom paired genotyping of HIV was possible, 8 of 11 had identical patterns in both CSF and plasma at baseline, whereas at week 48, only 1 of 9 children had similar patterns. Neurologic abnormalities were observed in 83% of children at baseline but only 35% of children at week 48 (P = .004), suggesting a benefit of treatment. Conclusions: Antiretroviral therapy was associated with a decline in CSF HIV RNA and an improvement in neurologic status. The development of genotypic mutations was different in CSF and plasma, suggesting discordant viral evolution. These results suggest that antiretroviral treatment in children should include agents with activity in the CNS.

AB - Objectives: This study evaluated the effect of treatment with abacavir/lamivudine/zidovudine versus lamivudine/zidovudine on cerebrospinal fluid (CSF) human immunodeficiency virus (HIV) RNA and clinical manifestations of HIV encephalopathy in children. Study design: HIV-infected children 7 months to 10 years of age (n = 23) were studied. CSF and plasma were obtained at baseline and weeks 8, 16, and 48. Genotype analysis of HIV was attempted at baseline and week 48. Neurologic evaluations were performed at baseline and weeks 16, 32, and 48. Results: At baseline, 83% of children had >2.00 log10 copies/mL HIV RNA in CSE but only 10% had HIV RNA measurable at week 48. Among children in whom paired genotyping of HIV was possible, 8 of 11 had identical patterns in both CSF and plasma at baseline, whereas at week 48, only 1 of 9 children had similar patterns. Neurologic abnormalities were observed in 83% of children at baseline but only 35% of children at week 48 (P = .004), suggesting a benefit of treatment. Conclusions: Antiretroviral therapy was associated with a decline in CSF HIV RNA and an improvement in neurologic status. The development of genotypic mutations was different in CSF and plasma, suggesting discordant viral evolution. These results suggest that antiretroviral treatment in children should include agents with activity in the CNS.

UR - http://www.scopus.com/inward/record.url?scp=0036066839&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036066839&partnerID=8YFLogxK

U2 - 10.1067/mpd.2002.125007

DO - 10.1067/mpd.2002.125007

M3 - Article

C2 - 12091849

AN - SCOPUS:0036066839

VL - 141

SP - 36

EP - 44

JO - Journal of Pediatrics

JF - Journal of Pediatrics

SN - 0022-3476

IS - 1

ER -